{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T13:20:29Z","timestamp":1751203229540,"version":"3.40.3"},"reference-count":66,"publisher":"Veterinary World","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet World"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Background and Aim: Tuberculosis (TB) remains a significant global health challenge, with increasing incidences of drug-sensitive (DS) and multidrug-resistant (MDR) TB. In addition, Mycobacterium bovis-induced zoonotic TB (zTB) presents treatment difficulties due to its resistance to pyrazinamide and the prolonged treatment duration required. This study aims to evaluate the antitubercular potential of \u03b2-aminopropioamidoxime derivatives against DS and MDR Mycobacterium tuberculosis and M. bovis strains, and utilizing the SwissADME prognostic tool to predict the drug- and lead-likeness of the described compounds.\n\nMaterials and Methods: Six \u03b2-aminopropioamidoxime derivatives were synthesized through O-aroylation of amidoxime followed by dehydration to form 1,2,4-oxadiazoles. The compounds were tested in vitro against DS, MDR M. tuberculosis, and M. bovis using Sotton\u2019s liquid medium and subcultured on dense Lowenstein-Jensen medium. SwissADME was used to predict drug-likeness and pharmacokinetic properties.\n\nResults: The derivatives exhibited significant antitubercular activity, with in vitro efficacy 5\u2013100 times greater than rifampicin. 1,2,4-oxadiazoles with para-bromo and meta-chloro substituents demonstrated the highest activity against DS and MDR M. tuberculosis, while O-para-toluoyl-\u03b2-(morpholin-1-yl)propioamidoxime salts (hydrochloride, oxalate and citrate) were 10 times more active against M. bovis. SwissADME analysis confirmed favorable pharmacokinetic properties, including high gastrointestinal absorption and drug-likeness, with lead-likeness identified in four compounds.\n\nConclusion: The study presents \u03b2-aminopropioamidoxime derivatives as promising candidates for antitubercular therapy against both human and zTB. Their enhanced activity, oral bioavailability, and potential integration into new treatment regimens underscore their therapeutic relevance. Further in vivo studies are recommended to validate their efficacy and safety for clinical applications.\n\nKeywords: antitubercular agents, Mycobacterium bovis, Mycobacterium tuberculosis, SwissADME, tuberculosis, \u03b2-aminopropioamidoximes.<\/jats:p>","DOI":"10.14202\/vetworld.2025.731-745","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T09:09:18Z","timestamp":1743498558000},"page":"731-745","update-policy":"https:\/\/doi.org\/10.14202\/vetworld.2022.policies","source":"Crossref","is-referenced-by-count":2,"title":["\u03b2-Aminopropioamidoximes derivatives as potential antitubercular agents against anthropozoonotic infections caused by Mycobacterium tuberculosis and Mycobacterium bovis"],"prefix":"10.14202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1900-1228","authenticated-orcid":false,"given":"Lyudmila","family":"Kayukova","sequence":"first","affiliation":[{"name":"JSC A.B. Bekturov Institute of Chemical Sciences, Laboratory of Chemistry of Synthetic and Natural Drug Substances, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3130-9812","authenticated-orcid":false,"given":"Venera","family":"Bismilda","sequence":"additional","affiliation":[{"name":"National Scientific Center of Phthisiopulmonology, Ministry of Health of the Republic of Kazakhstan, National Reference Bacteriological Laboratory, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0982-1863","authenticated-orcid":false,"given":"Kairat","family":"Turgenbayev","sequence":"additional","affiliation":[{"name":"LLP Scientific and Production Center BioVet, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9664-0912","authenticated-orcid":false,"given":"Asem","family":"Uzakova","sequence":"additional","affiliation":[{"name":"JSC A.B. Bekturov Institute of Chemical Sciences, Laboratory of Chemistry of Synthetic and Natural Drug Substances, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-0695","authenticated-orcid":false,"given":"Gulnur","family":"Baitursynova","sequence":"additional","affiliation":[{"name":"JSC A.B. Bekturov Institute of Chemical Sciences, Laboratory of Chemistry of Synthetic and Natural Drug Substances, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2354-9878","authenticated-orcid":false,"given":"Umirzak","family":"Jussipbekov","sequence":"additional","affiliation":[{"name":"JSC A.B. Bekturov Institute of Chemical Sciences, Laboratory of Chemistry of Synthetic and Natural Drug Substances, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1311","authenticated-orcid":false,"given":"Meruyert","family":"Mukanova","sequence":"additional","affiliation":[{"name":"JSC A.B. Bekturov Institute of Chemical Sciences, Laboratory of Chemistry of Synthetic and Natural Drug Substances, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1164-2661","authenticated-orcid":false,"given":"Lyailya","family":"Chingissova","sequence":"additional","affiliation":[{"name":"National Scientific Center of Phthisiopulmonology, Ministry of Health of the Republic of Kazakhstan, National Reference Bacteriological Laboratory, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2721-997X","authenticated-orcid":false,"given":"Gulnur","family":"Dyussembayeva","sequence":"additional","affiliation":[{"name":"JSC A.B. Bekturov Institute of Chemical Sciences, Laboratory of Chemistry of Synthetic and Natural Drug Substances, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2722-2020","authenticated-orcid":false,"given":"Assiya","family":"Borsynbayeva","sequence":"additional","affiliation":[{"name":"LLP Scientific and Production Center BioVet, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5482-7621","authenticated-orcid":false,"given":"Azamat","family":"Yerlanuly","sequence":"additional","affiliation":[{"name":"JSC A.B. Bekturov Institute of Chemical Sciences, Laboratory of Chemistry of Synthetic and Natural Drug Substances, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9983-124X","authenticated-orcid":false,"given":"Ablay","family":"Auyezov","sequence":"additional","affiliation":[{"name":"National Scientific Center of Phthisiopulmonology, Ministry of Health of the Republic of Kazakhstan, National Reference Bacteriological Laboratory, Almaty, Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5308","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"ref0","unstructured":"WHO. (2023) Global Tuberculosis Report 2023. Geneva: World Health Organization; 2023. Available from: http:\/\/www.who.int . Retrieved on 06-04-2024."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Cilloni, L., Fu, H., Vesga, J.F., Dowdy, D., Pretorius, C., Ahmedov, S., Nair, A., Mosneaga, S., Masini, A., Sahu, S. and Arinaminpathy, N. (2020) The potential impact of the COVID-19 pandemic on the Tuberculosis epidemic a modelling analysis. EClinicalMedicine, 28: 100603.","DOI":"10.1016\/j.eclinm.2020.100603"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Kayukova, L.A. and Berikova, E.A. (2020) Modern anti-TB drugs and their classification. Part I. First-line drugs (review). Pharm. Chem. J., 54(6): 555\u2013563.","DOI":"10.1007\/s11094-020-02239-2"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Maitre, T., Baulard, A., Aubry, A. and Veziris, N. (2024) Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis. Infect. Dis. Now, 54(1): 104807.","DOI":"10.1016\/j.idnow.2023.104807"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Pontali, E., Raviglione, M.C., Migliori, G.B. and The Writing Group Members of the Global TB Network Clinical Trials Committee. (2019) Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur. Respir. Rev., 28: 190035.","DOI":"10.1183\/16000617.0035-2019"},{"key":"ref5","unstructured":"United Nations. (2023) Political Declaration of the High-level Meeting of the General Assembly on the Fight against Tuberculosis. United Nations, New York. Available from: https:\/\/www.un.org\/pga\/77\/wp-content\/uploads\/sites\/105\/2023\/09\/tb-final-text.pdf . Retrieved on 06-04-2024."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Akalu, T., Clements, A., Wolde, H. and Alene K.A. (2023) Economic burden of multidrug-resistant tuberculosis on patients and households: A global systematic review and meta-analysis. Sci. Rep., 13: 22361.","DOI":"10.1038\/s41598-023-47094-9"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"WHO Launches the TB Research Tracker, an Online Platform to Track Progress in TB Research. Available from: https:\/\/www.who.int\/news\/item\/05-06-2023-who-launches-the-tb-research-tracker--an-online-platform-to-track-progress-in-tb-research. Retrieved on 06-04-2024.","DOI":"10.1371\/journal.pgph.0003655"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"WHO. (2022) WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-resistant Tuberculosis Treatment, 2022 Update. World Health Organization, Geneva. Available from: http:\/\/apps.who.int\/iris . Retrieved on 06-04-2024.","DOI":"10.37774\/9789275327869"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Barbier, M. and Wirth, T. (2016) The Evolutionary history, demography, and spread of the Mycobacterium tuberculosis complex. Microbiol Spectr., 4(4): 2820.","DOI":"10.1128\/microbiolspec.tbtb2-0008-2016"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Brites, D., Loiseau, C., Menardo, F., Borrell, S., Boniotti, M.B., Warren, R., Dippenaar, A., Parsons, S.D.C., Beisel, C., Behr, M.A., Fyfe, J.A., Coscolla, M. and Gagneux, S. (2018) A new phylogenetic framework for the animal adapted mycobacterium tuberculosis complex. Front. Microbiol., 9: 2820.","DOI":"10.1101\/384263"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Orgeur, M. and Brosch, R. (2018) Evolution of virulence in the Mycobacterium tuberculosis complex. Curr. Opin. Microbiol., 41: 68\u201375.","DOI":"10.1016\/j.mib.2017.11.021"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Otto-Knapp, R., Schenkel, K. and Bauer, T. (2016) Standard therapy of tuberculosis. Internist (Berl.), 57: 117\u2013125.","DOI":"10.1007\/s00108-016-0059-1"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Lan, Z., Bastos, M. and Menzies, D. (2016) Treatment of human disease due to Mycobacterium bovis: A systematic review. Eur. Respir. J., 48: 1500\u20131503.","DOI":"10.1183\/13993003.00629-2016"},{"key":"ref14","unstructured":"World Health Organization. (2018) Global Tuberculosis Report 2018. Available from: http:\/\/www.who.int.publications-detail-redirect\/9789241565646 .  Retrieved on 06-04-2024."},{"key":"ref15","unstructured":"WHO. (2019) WHO Global Tuberculosis Report. Available from: https:\/\/www.who.int\/tb\/publications\/global_report\/en . Retrieved on 06-04-2024."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"El-Sayed, A., El-Shannat, S., Kamel, M., Castaneda-Vazquez, M.A. and Castaneda-Vazquez, H. (2016) Molecular epidemiology of Mycobacterium bovis in humans and cattle. Zoonoses Public Health, 63: 251\u2013538.","DOI":"10.1111\/zph.12242"},{"key":"ref17","unstructured":"WOAH Terrestrial Manual 2022 Chapter 3.1.1 3 Mammalian Tuberculosis (Infection with mycobacterium tuberculosis complex). Available from: https:\/\/www.woah.org\/en\/home\/bovine-tuberculosis. Retrieved on 29-06-2024."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Turgenbayev. K.A., Borsynbayeva, A.M., Plazun, A.A., Turgenbayev, R.K. (2021) Tuberculosis prevalence in animals and humans in the Republic of Kazakhstan. Vet. World, 14(9): 2362\u20132370.","DOI":"10.14202\/vetworld.2021.2362-2370"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Zinsstag, J., Schelling, E., Roth, F. and Kazwala, R.R. (2008) Economics of Bovine Tuberculosis: Mycobacterium bovis Infection in Animals and Humans. 2nd ed. Iowa State University Press, Ames, p68\u201383.","DOI":"10.1002\/9780470344538.ch9"},{"key":"ref20","unstructured":"WHO. Available from: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb). Retrieved on 05-20-2024."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Walther, B., Schaufle, K., Wieler, L.H. and L\u00fcbke-Becker, A. (2022) Zoonotic and multidrug-resistant bacteria in companion animals challenge infection medicine and biosecurity. In: Sing, A. (ed) Zoonoses: Infections Affecting Humans and Animals. Springer, Cham.","DOI":"10.1007\/978-3-030-85877-3_17-1"},{"key":"ref22","unstructured":"One Health Initiative. Available from: http:\/\/www.onehealthinitiative.com. Retrieved on 12-06-2024."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"de Macedo Couto, R., Santana, G.O., Ranzani, O.T. and Waldman, E.A. (2022) One Health and surveillance of zoonotic tuberculosis in selected low-income, middle-income and high-income countries: A systematic review. PLoS Negl. Trop. Dis., 16(6): e0010428.","DOI":"10.1371\/journal.pntd.0010428"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Berry, C., du Cros, P., Fielding, K., Gajewski, S., Kazounis, E., McHugh, T.D., Merle, C., Motta, I., Moore, D.A.J. and Nyang'wa, B.T. (2022) TB-PRACTECAL: Study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials, 23(1): 484.","DOI":"10.21203\/rs.3.rs-992464\/v1"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Koul, A.,Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., G\u00f6hlmann, H.W.H., Willebrords, R., Poncelet, A., Guillemont, J., Bald, D. and Andries, K. (2008) Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem., 283: 25273\u201325280.","DOI":"10.1074\/jbc.m803899200"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Zheng, H., He, W., Jiao, W., Xia, H., Sun, L., Wang, S., Xiao, J., Ou, X., Zhao, Y. and Shen, A. (2021) Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China. BMC Infect. Dis., 21: 330.","DOI":"10.21203\/rs.3.rs-159138\/v1"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Nuermberger, E., Tyagi, S., Tasneen, R., Williams, K.N., Almeida, D., Rosenthal, I. and Grosset, J.H. (2008) Powerful bactericidal and sterilizing activity of a regimen containing pa-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother., 52(4): 1522\u20131524.","DOI":"10.1128\/aac.00074-08"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Yang, C., Lei, H., Wang, D., Meng, X., He., J., Tong, A., Zhu, L., Jiang, Y. and Dong, M. (2012) In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China. Jpn J. Infect. Dis., 65(3): 240\u2013242.","DOI":"10.7883\/yoken.65.240"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Somasundaram, S. and Paramasivan, N.C. (2006) Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods. Chemotherapy, 52(4): 190\u2013195.","DOI":"10.1159\/000093486"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Reddy, V.M., O\u2019Sullivan, J.F. and Gangadharam, P.R. (1999) Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother., 43(5): 615\u2013623.","DOI":"10.1093\/jac\/43.5.615"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"McNevin, M. and Higgins, J. (2015) Strategies and methods for drug candidate phase optimization in discovery space. In: Templeton, A., Byrn, S., Haskell, R., Prisinzano, T. (eds) Discovering and Developing Molecules with Optimal Drug-like Properties. Vol. 15. Springer, New York, p. 209\u2013240.","DOI":"10.1007\/978-1-4939-1399-2_7"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Okezue, M., Bogdanowich-Knipp, S., Smith, D., Zeller, M., Byrn, S., Smith, P., Purcell, D.K. and Clase, K. (2021) Salts and polymorph screens for bedaquiline. AAPSPharm. Sci. Tech., 22: 228.","DOI":"10.1208\/s12249-021-02106-7"},{"key":"ref33","unstructured":"Dailymed - Linezolid - Linezolid Granule, for Suspension. Camber Pharmaceuticals, Inc. (2022) Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a89a37ec-a736-464b-a83a-84bef6ccd702. Retrieved on 04-08-2024."},{"key":"ref34","unstructured":"Moxifloxacin Injection - Product Monograph. (2020) Moxifloxacin Injection 400 mg\/250 mL (1.6 mg\/mL) (as Moxifloxacin Hydrochloride) Antibacterial Agent. Fresenius Kabi Canada Ltd., Toronto, ON."},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Stadler, J.A.M., Maartens, G., Meintjes, G. and Wasserman, S. (2023) Clofazimine for the treatment of tuberculosis. Front. Pharmacol., 14: 1100488.","DOI":"10.3389\/fphar.2023.1100488"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Lenaerts, A.J., Gruppo, V., Marietta, K.S., Johnson, C.M., Driscoll, D.K., Tompkins, N.M., Rose, J.D., Reynolds, R.C. and Orme, I.M. (2005) Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother., 49(6): 2294\u20132301.","DOI":"10.1128\/aac.49.6.2294-2301.2005"},{"key":"ref37","unstructured":"New Tuberculosis Treatments (Drugs and Regimens). (2022) Available from: https:\/\/drewisdope.com\/new-tuberculosis-treatments. Retrieved on 01-04-2025."},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Bhagwat A, Deshpande A and Parish T (2022) How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery. Front. Cell. Infect. Microbiol. 12: 974101.","DOI":"10.3389\/fcimb.2022.974101"},{"key":"ref39","unstructured":"World Health Organization. (2020) Global Tuberculosis Report. WHO, Geneva."},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Kayukova, L.A., Orazbaeva, M.A., Bismilda, V.L. and Chingisova, L.T. (2010) Synthesis and antituberculosis activity of O-aroyl-\u03b2-(4-phenylpiperazin-1-yl)propioamidoximes. Pharm. Chem. J., 44: 356\u2013359.","DOI":"10.1007\/s11094-010-0467-9"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Kayukova, L., Jussipbekov, U. and Praliyev, K. (2020) Amidoxime Derivatives with Local Anesthetic, Antitubercular, and Antidiabetic Activity. IntechOpen, London.","DOI":"10.5772\/intechopen.90002"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Uzakova, A.B., Kayukova, L.A., Poroikov, B.B. and Praliev. R.D. (2018) A Comparison of the data of bioinformatics and experimental in vitro antitubercular activity of the new \u03b2-aminopropioamidoximes library. Res. J. Pharm. Tech., 11(9): 4003\u20134009.","DOI":"10.5958\/0974-360x.2018.00736.9"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Kayukova, L.A., Zhumadildaeva, I.S. and Praliyev, K.D. (2002) Cyclization of O-benzoyl-\u03b2-piperidinopropionamidoximes to form 5-phenyl-3-(\u03b2-piperidino)ethyl-1,2,4-oxadiazoles. Russ. Chem. Bull., 51: 2100\u20132105.","DOI":"10.1002\/chin.200320144"},{"key":"ref44","unstructured":"Kayukova, L.A., Myrzabek, A.B., Baitursynova, G.P., Ergaliyeva, E.M. and Kurmangaliyeva, A.B. (2022) JSC Institute of Chemical Sciences. A Method for Producing of \u03b2-(morpholin-1-yl) Propioamidoxime, an Intermediate Product in the Synthesis of a Substance with Anti-tubercular and Anti-diabetic activity. Kazakhstan Patent for Utility Model No. 6887."},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Golyshevskaya, V.I., Guskova, T.A., Shulgina, M.V., Martynova, L.P., Mozhokina, G.N. and Sokolova, G.B. (2012) Chapter 34: Methodological recommendations for studying the anti-tuberculosis activity of drugs. In: Korobov, N.V., (ed) The Digest of Articles: Guidelines for Conducting of Preclinical Studies of Drugs. Part 1., Vol. 1. Publication of the Federal State Budgetary Institution Scientific Center for Expertise of Medical Products of the Ministry of Health of the Russian Federation, Moscow, p566\u2012575.","DOI":"10.33920\/med-01-2303-06"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Daina, A., Michielin, O. and Zoete, V. (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep., 7: 42717.","DOI":"10.1038\/srep42717"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Ritchie, T.J., Ertl, P. and Lewis, R. (2011) The graphical representation of ADME-related molecule properties for medicinal chemists. Drug Discov. Today, 16: 65\u201372.","DOI":"10.1016\/j.drudis.2010.11.002"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Attique, S.A., Hassan, M., Usman, M., Atif, R.M., Mahboob, S., Al-Ghanim, K.A., Bilal, M. and Nawaz, M.Z. (2019) A Molecular docking approach to evaluate the pharmacological properties of natural and synthetic treatment candidates for use against hypertension. Int. J. Environ. Res. Public Health, 16(6): 923.","DOI":"10.3390\/ijerph16060923"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Bello, A., Adamu, U., Gideon, U., Shallangwa, A. and Uba, S. (2020) Design of potential anti-melanoma agents against SK-MEL-5 cell line using QSAR modeling and molecular docking methods. SN Appl. Sci., 2: 815.","DOI":"10.1007\/s42452-020-2620-8"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 46(1\u20133): 3\u201326.","DOI":"10.1016\/s0169-409x(96)00423-1"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Ertl, P., Rohde, B. and Selzer, P. (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem., 43: 3714\u20133717.","DOI":"10.1021\/jm000942e"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Martin, Y.C. (2005) A Bioavailability score. J. Med. Chem., 48: 3164\u20133170.","DOI":"10.1021\/jm0492002"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Sakko, Y., Madikenova, M., Kim, A., Syssoyev, D., Mussina, K., Gusmanov, A., Zhakhina, G., Yerdessov, S., Semenova, Y., Crape, B.L., Sarria-Santamera, A. and Gaipov, A. (2023) Epidemiology of tuberculosis in Kazakhstan: data from the Unified National Electronic Healthcare System 2014\u20132019. BMJ Open., 13(10): e074208.","DOI":"10.1136\/bmjopen-2023-074208"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Shaweno D, Worku A. (2012) Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study. BMC Res. Notes, 5: 682.","DOI":"10.1186\/1756-0500-5-682"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Ye, Z., Li, L., Yang, L., Zhuang, L., Aspatwar, A., Wang, L. and Gong, W. (2024) Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspective. Exploration (Beijing), 4(5): 20230138.","DOI":"10.1002\/exp.20230138"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Zhang, L., Zhang, X., Li, H., Chen, G. and  Zhu, M. (2019) Acute ischemic stroke in young adults with tuberculous meningitis. BMC Infect. Dis. 19: 362.","DOI":"10.1186\/s12879-019-4004-5"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Xiao, J., Ge, J., Zhang, D., Lin, X., Wang, X., Peng, L. and Chen, L. (2022) Clinical characteristics and outcomes in chronic kidney disease patients with tuberculosis in China: A retrospective cohort study. Int. J. Gen. Med., 15: 6661-6669.","DOI":"10.2147\/ijgm.s367090"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Jaisi, B. (2018) Prevalence of tuberculosis in patients with liver cirrhosis. J. Nepal Health Res. Counc. 15(3): 264-267.","DOI":"10.3126\/jnhrc.v15i3.18852"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Darisheva, M., Tracy, M., Terlikbayeva, A.,  Zhussupov, B.,  Schluger,  N. and McCrimmon,  T. (2020) Knowledge and attitudes towards ambulatory treatment of tubercul\u043esis in Kazakhstan. BMC Health Serv. Res., 20: 563.","DOI":"10.1186\/s12913-020-05413-0"},{"key":"ref60","unstructured":"Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis. Retrieved on 03-01-2025."},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"World Health Organization. The Moscow Declaration. First WHO Global Ministerial Conference Ending Tuberculosis in the Sustainable Development Era: A Multisectoral Response. Moscow, Russian Federation, 16\u201317 November 2017. http:\/\/www.who.int\/tb\/features_archive\/ZeroDraft-DeclarationEndTBMinisterial Conference.pdf?ua=1. Retrieved on 03-01-2025.","DOI":"10.21292\/2075-1230-2017-95-4-5-6"},{"key":"ref62","unstructured":"Ryskulov, G.P., Adenov, M., Turdaliyeva, B. and Maryandyshev, A.O. (2023) Short term regimens for drug-resistant tuberculosis: A review of clinical effectiveness and cost-effectiveness. Phthisiopulmonology, 2: 106\u2012112."},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Keertan, D., Christoph, L. (2024) Towards shorter, safer, flexible, and more effective treatment regimens for drug-resistant tuberculosis. Lancet Respir. Med., 12(12): 939-941.","DOI":"10.1016\/s2213-2600(24)00300-x"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Islamov, R., Kerimzhanova, B. and Ilin, A. (2019). New Antituberculosis Drug FS-1. Medicinal Chemistry. IntechOpen.","DOI":"10.5772\/intechopen.80795"},{"key":"ref65","unstructured":"FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis (FS-1). ClinicalTrials.gov ID NCT02607449. Last Update Posted 24-05-2022."}],"container-title":["Veterinary World"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/veterinaryworld.org\/Vol.18\/March-2025\/19.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T09:11:30Z","timestamp":1743498690000},"score":1,"resource":{"primary":{"URL":"https:\/\/veterinaryworld.org\/Vol.18\/March-2025\/19.php"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":66,"URL":"https:\/\/doi.org\/10.14202\/vetworld.2025.731-745","relation":{},"ISSN":["2231-0916","0972-8988"],"issn-type":[{"value":"2231-0916","type":"electronic"},{"value":"0972-8988","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-2-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-3-31","order":2,"name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}